CYCLERION THERAPEUTICS INC (CYCN) Stock Price, Quote, News and Overview
NASDAQ:CYCN - Nasdaq - US23255M2044 - Common Stock - Currency: USD
CYCN Quote, Performance and Key Statistics
NASDAQ:CYCN (5/23/2025, 9:25:15 PM)
3.2701
+0.02 (+0.62%)
The current stock price of CYCN is 3.2701 USD. In the past month the price increased by 0.62%. In the past year, price increased by 10.48%.
CYCN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.06B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About CYCN
Company Profile
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The firm operates through the human therapeutics segment. The firm is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The firm is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Company Info
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Peter M. Hecht
Employees: 1
Phone: 16176217722
CYCLERION THERAPEUTICS INC / CYCN FAQ
What is the stock price of CYCLERION THERAPEUTICS INC today?
The current stock price of CYCN is 3.2701 USD. The price increased by 0.62% in the last trading session.
What is the ticker symbol for CYCLERION THERAPEUTICS INC stock?
The exchange symbol of CYCLERION THERAPEUTICS INC is CYCN and it is listed on the Nasdaq exchange.
On which exchange is CYCN stock listed?
CYCN stock is listed on the Nasdaq exchange.
What is CYCLERION THERAPEUTICS INC worth?
CYCLERION THERAPEUTICS INC (CYCN) has a market capitalization of 10.50M USD. This makes CYCN a Nano Cap stock.
How many employees does CYCLERION THERAPEUTICS INC have?
CYCLERION THERAPEUTICS INC (CYCN) currently has 1 employees.
What are the support and resistance levels for CYCLERION THERAPEUTICS INC (CYCN) stock?
CYCLERION THERAPEUTICS INC (CYCN) has a support level at 3.03 and a resistance level at 3.28. Check the full technical report for a detailed analysis of CYCN support and resistance levels.
Should I buy CYCLERION THERAPEUTICS INC (CYCN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYCN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYCN, evaluating the profitability, health, valuation and growth aspects
- CYCLERION THERAPEUTICS INC (CYCN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYCLERION THERAPEUTICS INC (CYCN) Sales and EPS estimates to see what analysts future expectations are.
- CYCLERION THERAPEUTICS INC (CYCN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYCLERION THERAPEUTICS INC (CYCN) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYCLERION THERAPEUTICS INC (CYCN) Stock Chart to make your own analysis
- CYCLERION THERAPEUTICS INC (CYCN) Latest news and press-releases to stay up to date.
Does CYCLERION THERAPEUTICS INC (CYCN) stock pay dividends?
CYCN does not pay a dividend.
When does CYCLERION THERAPEUTICS INC (CYCN) report earnings?
CYCLERION THERAPEUTICS INC (CYCN) will report earnings on 2025-08-05.
What is the Price/Earnings (PE) ratio of CYCLERION THERAPEUTICS INC (CYCN)?
CYCLERION THERAPEUTICS INC (CYCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
What is the Short Interest ratio of CYCLERION THERAPEUTICS INC (CYCN) stock?
The outstanding short interest for CYCLERION THERAPEUTICS INC (CYCN) is 2.32% of its float. Check the ownership tab for more information on the CYCN short interest.
CYCN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CYCN. When comparing the yearly performance of all stocks, CYCN is one of the better performing stocks in the market, outperforming 85.16% of all stocks.
CYCN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYCN. CYCN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CYCN Financial Highlights
Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 46.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.93% | ||
| ROE | -34.54% | ||
| Debt/Equity | 0 |
CYCN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CYCN. The Buy consensus is the average rating of analysts ratings from 7 analysts.